Dr Reddys Laboratories share price
Dr Reddys Laboratories is trading -0.64% lower at Rs 6,759.05 as compared to its last closing price. Dr Reddys Laboratories has been trading in the price range of 6,825.20 & 6,736.60. Dr Reddys Laboratories has given 17.36% in this year & -0.89% in the last 5 days.
Dr Reddys Laboratories has TTM P/E ratio 19.15 as compared to the sector P/E of 29.10.There are 33 analysts who have initiated coverage on Dr Reddys Laboratories. There are 6 analysts who have given it a strong buy rating & 5 analysts have given it a buy rating. 9 analysts have given the stock a sell rating.
The company posted a net profit of 1,392.40 Crores in its last quarter.
Listed peers of Dr Reddys Laboratories include Cipla (0.86%), Zydus Lifesciences (2.64%), Dr Reddys Laboratories (-0.64%) etc.
Dr Reddys Laboratories has a 26.65% promoter holding & 73.18% public holding.The Mutual Fund holding in Dr Reddys Laboratories was at 7.88% in 30 Jun 2024. The MF holding has increased from the last quarter. The FII holding in Dr Reddys Laboratories was at 27.68% in 30 Jun 2024. The FII holding has decreased from the last quarter.
Dr Reddys Laboratories share price range
|
| ||||
|
| ||||
Dr Reddys Laboratories share Key Metrics
Market Cap ( ₹ Cr.) | 1,13,320.00 | ||||||||||||||||||
|
|
Dr Reddys Laboratories stock Analysis
1 Week | -0.89% |
3 Months | 9.67% |
6 Month | 16.49% |
YTD | 17.36% |
1 Year | 20.63% |
- 21%Moderate risk
- 21%Moderate risk
- 21%Moderate risk
- 21%Moderate risk
- 21%Moderate risk
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Ratings | Current | 1 W Ago | 1 M Ago | 3 M Ago |
---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 5 |
Buy | 5 | 5 | 5 | 7 |
Hold | 9 | 10 | 9 | 11 |
Sell | 9 | 7 | 8 | 8 |
Strong Sell | 4 | 4 | 4 | 3 |
Total | 33 | 32 | 32 | 34 |
Technical Trends
Long TermConsiders price movement over the last 6 months
Short TermConsiders price movement over the last 1-2 weeks
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Dr Reddys Laboratories share price news
New businesses and partnerships hold the key to Dr Reddy's growth
2 min read .08:20 PM ISTDr. Reddy’s to promote and distribute Sanofi’s vaccine brands
1 min read .07:59 PM ISTDr Reddy's Laboratories Q3 Results: Net profit rises 10.6% to ₹1,379 crore; 5 key highlights
2 min read .07:04 PM ISTDr Reddys Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
Period | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
Total Revenue | 28,011.10 | 24,669.70 | 21,545.20 | 19,047.50 |
Selling/ General/ Admin Expenses Total | 11,869.00 | 8,204.80 | 7,339.90 | 6,385.10 |
Depreciation/ Amortization | 1,470.00 | 1,250.20 | 1,165.20 | 1,228.80 |
Total Operating Expense | 21,395.60 | 19,449.80 | 18,942.70 | 16,402.20 |
Operating Income | 6,615.50 | 5,219.90 | 2,602.50 | 2,645.30 |
Net Income Before Taxes | 7,201.00 | 6,048.50 | 3,061.40 | 2,883.50 |
Net Income | 5,577.90 | 4,507.30 | 2,182.50 | 1,951.60 |
Diluted Normalized EPS | 327.52 | 279.44 | 165.95 | 142.73 |
Dr Reddys Laboratories forecast
Dr Reddys Laboratories Technical
5 Day 6,853.67 |
10 Day 6,777.77 |
20 Day 6,648.30 |
50 Day 6,238.87 |
100 Day 6,193.83 |
300 Day 5,971.18 |
Dr Reddys Laboratories Futures and Options
- FUTURES
- OPTIONS
Share Price
6,799.00INR-50.90(-0.74%)Open Interest
2.83 MINR14.88 K(28.60%)
- Open6,777.25
- High6,866.45
- Low6,777.25
- Prev Close6,849.90
- Contracts Traded4.05 K
- Turnover in (Rs Lakhs)34.55 K
HDFC Retirement Savings Fund - Hybrid Debt Plan - Regular Plan
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth
Dr Reddys Laboratories Corporate actions
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
Meeting Date | Purpose |
27-Jul-24 | Quarterly Results & Stock Split |
07-May-24 | Audited Results & Final Dividend |
30-Jan-24 | Quarterly Results |
27-Oct-23 | Quarterly Results |
26-Jul-23 | Quarterly Results |
10-May-23 | Audited Results & Final Dividend |
25-Jan-23 | Quarterly Results |
28-Oct-22 | Quarterly Results |
28-Jul-22 | Quarterly Results |
19-May-22 | Audited Results & Final Dividend |
Meeting Date | Announcement On | Purpose |
15-Feb-24 | 15-Jan-24 | POM |
16-Nov-23 | 16-Oct-23 | POM |
27-Jul-23 | 10-May-23 | AGM |
29-Jul-22 | 20-May-22 | AGM |
29-Mar-22 | 25-Feb-22 | POM |
28-Jul-21 | 20-May-21 | AGM |
Announcement On | Record Date | Ex-Dividend | Dividend Value |
07-May-24 | - | 16-Jul-24 | 40 |
10-May-23 | - | 11-Jul-23 | 40 |
19-May-22 | - | 11-Jul-22 | 30 |
14-May-21 | - | 09-Jul-21 | 25 |
Ex-Splits | Old FV | New FV | Description |
- | 5 | 1 | Stock Split from Rs. 5/- to Re. 1/- |
Dr Reddys Laboratories Company profile
ABOUT Dr Reddys Laboratories
- Industry Biotechnology & Drugs
- ISIN INE089A01023
- BSE Code 500124
- NSE Code DRREDDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Dr Reddys Laboratories Management
- Kallam Reddy Chairman of the Board
- Gunupati Prasad Co-Chairman of the Board, Managing Director
- Erez Israeli Chief Executive Officer
- Parag Agarwal Chief Financial Officer
- Patrick Aghanian Chief Executive Officer, European Generics
- Milan Kalawadia Chief Executive Officer, North America
- M. Ramana Chief Executive Officer, Branded Markets (India and Emerging Countries)
- Archana Bhaskar Chief Human Resource Officer
- Phani Mitra B. Chief Information Officer
- Sushrut Kulkarni Global Head of Integrated Product Development Organisation
FAQs about Dr Reddys Laboratories share price
Dr Reddys Laboratories Quick Links
Dr Reddys Laboratories Dividend Dr Reddys Laboratories Bonus Dr Reddys Laboratories News Dr Reddys Laboratories AGM Dr Reddys Laboratories Rights Dr Reddys Laboratories Splits Dr Reddys Laboratories Board Meetings Dr Reddys Laboratories Key Metrics Dr Reddys Laboratories Shareholdings Dr Reddys Laboratories Profit Loss Dr Reddys Laboratories Balance Sheet Dr Reddys Laboratories Cashflow Dr Reddys Laboratories Q1 Results Dr Reddys Laboratories Q2 Results Dr Reddys Laboratories Q3 Results Dr Reddys Laboratories Q4 Results
Equity Quick Links
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks